Receptor Imaging in Oncology by Means of Nuclear Medicine: Current Status
- 1 September 2004
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (17), 3593-3607
- https://doi.org/10.1200/jco.2004.10.216
Abstract
To date, our understanding of the role of receptors and their cognate ligands in cancer is being successfully translated into the design and development of an arsenal of new, less toxic, and more specific anticancer drugs. Because most of these novel drugs are cytostatic, objective response as measured by morphologic imaging modalities (eg, computed tomography or magnetic resonance imaging) cannot be used as a surrogate marker for drug development or for clinical decision making. Positron emission tomography (PET) can be used to image and quantify the in vivo distribution of positron-emitting radioisotopes such as oxygen-15, carbon-11, and fluorine-18 that can be substituted or added into biologically relevant and specific receptor radioligands. Similarly, single-photon emission computed tomography (SPECT) can be used to image and quantify the in vivo distribution of receptor targeting compounds labeled with indium-111, technetium-99m, and iodine-123. By virtue of their whole-body imaging capacity and the absence of errors of sampling and tissue manipulation as well as preparation, both techniques have the potential to address locoregional receptor status noninvasively and repetitively. This article reviews available data on the in vivo evaluation of receptor systems by means of PET or SPECT for identifying and monitoring patients with sufficient receptor overexpression for tailored therapeutic interventions, and also for depicting tumor tissue and determining the currently largely unknown heterogeneity in receptor expression among different tumor lesions within and between patients.Keywords
This publication has 99 references indexed in Scilit:
- [18F]N-4′-Fluorobenzyl-4-(3-bromophenyl) acetamide for imaging the sigma receptor status of tumors: comparison with [18F]FDG and [125I]IUDRNuclear Medicine and Biology, 2001
- Inhibition of growth of MDA-MB-231 human breast cancer xenografts in nude mice by bombesin/gastrin-releasing peptide (GRP) antagonists RC-3940-II and RC-3095European Journal Of Cancer, 1998
- 123I-vasoactive intestinal peptide (VIP) receptor scanning: Update of imaging results in patients with adenocarcinomas and endocrine tumors of the gastrointestinal tractNuclear Medicine and Biology, 1996
- Synthesis, in vitro validation and in vivo pharmacokinetics of [125I]N-[2-(4-Iodophenyl)Ethyl]-N-Methyl-2-(1-Piperidinyl) ethylamine: A high-affinity ligand for imaging sigma receptor positive tumorsNuclear Medicine and Biology, 1996
- Somatostatin receptor imaging in small cell lung cancerEuropean Journal Of Cancer, 1996
- Somatostatin receptor imaging of small cell lung cancer (SCLC) by means of 111In-DTPA octreotide scintigraphyEuropean Journal Of Cancer, 1995
- Imaging, biodistribution and therapy potential of Halogenated tamoxifen analoguesLife Sciences, 1994
- Growth factor and peptide receptors in small cell lung cancerLife Sciences, 1993
- Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivityEuropean Journal Of Cancer, 1993
- The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patientsEndocrine Reviews, 1992